Company intelligence / Profile preview
Porosome Therapeutics, Inc.
Boston, Massachusetts, United Statesporosome.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Porosome Therapeutics has demonstrated preclinical proof-of-concept restoring normal mucin secretion in organs affected by cystic fibrosis. Their lead program received FDA Orphan Drug Designation in early development. The company claims broad preclinical activity across multiple disease areas involving secretory dysfunction but has not reported clinical results yet.
- Therapeutic areas
- PulmonologyEndocrinologyImmunologyOncologyNeurology
- Modalities
- Small moleculesNanobodiesiPSC-derived cell therapies (beta cells)Protein/lipid reconstitution (porosome replacement)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Collaborations with leading scientists from academic/research institutions are mentioned but not named specifically. No major pharma partnerships disclosed yet.
Beyond the preview
Go deeper on Porosome Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Porosome Therapeutics, Inc..